Crescent Biopharma (CBIO)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from CBIO's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from Crescent Biopharma's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $1M | $75,000 | $10,000 | — | $11M |
| Net income | -$63M | -$47M | -$37M | -$38M | -$154M |
| Free cash flow | -$58M | -$47M | -$35M | -$31M | -$72M |
| EPS (diluted) | -$1.23 | -$0.89 | -$0.58 | -$0.59 | — |
| Operating margin | -5470.7% | -63204.4% | -392752.9% | — | -1407.5% |
Superinvestors who own CBIO
From each investor's latest 13F filing (what a 13F shows).
Insider buying
Open-market purchases by Crescent Biopharma's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Dec 4, 2025 | Fairmount Funds Management Llc |
1,360,000 | $13.41 | $18M |
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when CBIO trades at or below it.
New accounts get 7 days of Pro, price alerts included. No card needed.
In the full deep dive
Questions
Are Crescent Biopharma insiders buying the stock?
1 open-market insider purchase of CBIO in the last 12 months, from SEC Form 4 filings.
Companies like Crescent Biopharma
All Healthcare stocks · Biotechnology stocks · Stock lists
Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.